TWILIGHT-HF Subgroup Analysis Score
Exploratory : Explanation and context The TWILIGHT randomized trial tested whether, among high-risk patients who had completed 3 months of dual antiplatelet therapy after PCI, stopping aspirin and continuing ticagrelor monotherapy reduced clinically relevant bleeding without increasing ischemic events. The trial found a lower rate of BARC 2/3/5 bleeding with ticagrelor monotherapy versus ticagrelor plus aspirin, with